§ 01 Overview
Overview
Dual GLP-1 / glucagon receptor agonist showing strong weight loss and metabolic effects in late-stage trials, particularly in Asian populations.
Approved in China in 2025 for obesity and T2D. Ongoing trials in Western markets.
§ 02 Mechanism
Mechanism of action
Mazdutide activates both GLP-1 and glucagon receptors. The glucagon arm is hypothesized to increase energy expenditure and improve hepatic lipid handling, while GLP-1 drives appetite suppression and glycemic control.
- 01Substantial weight loss in Phase III (GLORY-1)
- 02Improvements in hepatic fat and liver enzymes
- 03Glycemic improvements in T2D
§ 03 Dosing
Dosing protocol
Standard Protocol
- Vial
- 10 mg
- BAC Water
- 1 ml BAC water
- Dose Range
- 3 – 9 mg weekly
- Starting Dose
- 3 mg weekly
- Route
- SubQ
- Frequency
- Weekly
- Cycle
- Titrate every 4 weeks.
§ 04 Evidence
Evidence & research
Approved in China in 2025 for obesity and T2D. Ongoing trials in Western markets.
FDA Status
Not FDA-approved. Approved in China (2025).
§ 06 News
In the news
8 articles from the last 12 months · updates hourly
Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide - MSN
Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide MSN
Innovent's First Mover Advantage for GLP-1 In China Will Be Long-Term Growth Driver - Morningstar
Innovent's First Mover Advantage for GLP-1 In China Will Be Long-Term Growth Driver Morningstar
Mazdutide Outperforms Dulaglutide in Type 2 Diabetes Trial - European Medical Journal
Mazdutide Outperforms Dulaglutide in Type 2 Diabetes Trial European Medical Journal
Top China Pharma and Biotech Stocks to Watch, According to Bernstein - Investing.com
Top China Pharma and Biotech Stocks to Watch, According to Bernstein Investing.com
Chinese researchers make significant progress in diabetes treatment - The Macau Post Daily
Chinese researchers make significant progress in diabetes treatment The Macau Post Daily
NJU Professor Zhu Dalong's team publishes research findings on T2D treatment in Nature-Nanjing University - nju.edu.cn
NJU Professor Zhu Dalong's team publishes research findings on T2D treatment in Nature-Nanjing University nju.edu.cn
Mazdutide versus placebo in Chinese adults with type 2 diabetes - Nature
Mazdutide versus placebo in Chinese adults with type 2 diabetes Nature
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes - Nature
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes Nature
§ 07 Sourcing
Sourcing & supply
Regulatory status
Investigational, no compounding path
Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk.
Research-use-only · 2
Swiss Chems
Established SARMs/peptide vendor. FDA warning letter Dec 2024 for GLP-1s. Weaker peptide QC than SARMs QC.
Summit Research
FDA warning letter December 2024 across multiple GLP-1s.
Listings are informational, not endorsement. Verify credentials and flags against FDA and PCAB databases before purchasing. Full directory & how to verify →
§ 09 Safety
Safety & side effects
Side effects
- 01Nausea
- 02GI effects typical of incretin class
Contraindications
None specified.